We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AutoZone (AZO) Q2 Earnings Up Y/Y, Revenues In Line
Read MoreHide Full Article
AutoZone, Inc. (AZO - Free Report) is a leading distributor of automotive replacement parts and accessories in the United States.
Earnings
In the second-quarter fiscal 2019 (Feb 9, 2019), AutoZone reported earnings of $11.49 per share. The bottom-line in the year-ago quarter was $10.38.
Revenues
The company reported net sales to $2.45 billion, higher than $2.41 billion recorded in the year-ago quarter. Further, the figure is in line with the Zacks Consensus Estimate.
Estimate Trend & Surprise History
Investors should note that stock has witnessed the Zacks Consensus Estimate for fiscal 2019 earnings being revised 0.24% upward over the last seven days.
AutoZone surpassed estimates in all trailing four quarters, leading to an average positive surprise was 8.8%.
Key Stats
During the reported quarter, the company opened 20 stores in the United States, one in Mexico and two in Brazil. As of Feb 9, 2019, it had 6,241 stores. Also, AutoZone repurchased 422,000 shares for $350 million, reflecting an average price of $830 per share.
Check back later for our full write up on AutoZone’s earnings report!
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
AutoZone (AZO) Q2 Earnings Up Y/Y, Revenues In Line
AutoZone, Inc. (AZO - Free Report) is a leading distributor of automotive replacement parts and accessories in the United States.
Earnings
In the second-quarter fiscal 2019 (Feb 9, 2019), AutoZone reported earnings of $11.49 per share. The bottom-line in the year-ago quarter was $10.38.
Revenues
The company reported net sales to $2.45 billion, higher than $2.41 billion recorded in the year-ago quarter. Further, the figure is in line with the Zacks Consensus Estimate.
Estimate Trend & Surprise History
Investors should note that stock has witnessed the Zacks Consensus Estimate for fiscal 2019 earnings being revised 0.24% upward over the last seven days.
AutoZone surpassed estimates in all trailing four quarters, leading to an average positive surprise was 8.8%.
Key Stats
During the reported quarter, the company opened 20 stores in the United States, one in Mexico and two in Brazil. As of Feb 9, 2019, it had 6,241 stores. Also, AutoZone repurchased 422,000 shares for $350 million, reflecting an average price of $830 per share.
Zacks Rank
AutoZone currently holds a Zacks Rank #3 (Hold), but that could change following its earnings report which has just released. Meanwhile, you can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Check back later for our full write up on AutoZone’s earnings report!
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>